Navigation Links
Indiana Tobacco Prevention and Cessation Awards Grant to Clarian Tobacco Control Center
Date:8/29/2008

Health Department advocating the new treatment Guideline:

Indiana ranks sixth among all states for adult smoking, with more than 1 million smokers estimated statewide. Sneegas strongly believes that Hoosiers want to quit smoking. Increased calls to the free Indiana Tobacco Quitline (1-800-QUIT-NOW) have increased in the past year; however, patients need support. Sneegas says health care providers are perfectly positioned to reach additional Hoosiers who want to quit smoking and provide them the necessary tools in order to be successful.

"Identifying smokers and providing them with brief advice and help with quitting in clinical practice are both very effective and cost effective," Deborah Hudson, program manager, CTCC, states. "Tobacco cessation is among the top three highest priority and cost-effective preventive services. As a healthcare professional, I found this to be true very early in my practice as a respiratory therapist. While we are asking about smoking status, national benchmarks show there is much room for improvement in delivering cessation assistance. The Community Intervention Trial for Smoking Cessation (COMMIT) showed that 75 percent of people were being asked about use, 49 percent advised to quit, and only 25 percent being offered assistance, like medications. When more than 60 percent of our smokers want to quit, we as health professionals need to be providing the means to assist them. It has become clear over the last decade that providing smoking cessation counseling may be similar to that of annual colon cancer screening, annual flu vaccinations, mammograms and cholesterol screening. This is why the Clarian Tobacco Control Center has launched an effort to assist healthcare providers in integrating evidence-based components that will allow them to provide brief cessation intervention."

CTCC will use the ITPC grant to ensure that Hoosier patients that smoke are treated for their disease, alongside any additional health issues
'/>"/>

SOURCE Indiana Tobacco Prevention and Cessation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. WellPoint and M-Plan Enter Into Endorsement Agreement as M-Plan Announces Exit From the Commercial HMO Business in Indiana
2. EPA: Nine Indiana Counties Now Meet the Health Standard for Smog
3. Indiana Attorney General Steve Carter Addresses Drunk Driving and Underage Drinking in New Radio Campaign
4. Indiana Legislature Should Protect All Workers from Secondhand Smoke
5. Tobacco-Free Kids Indiana Action Fund Launches Campaign in Support of Angela Mansfield and Scott Keller for Indianapolis City-County Council
6. Community Health Network of Indianapolis Completes System-Wide Conversion to Masimo SET Pulse Oximetry Technology
7. EPA Awards Grant to American Lung Association of Indiana for Community Environmental Health Initiative
8. Medco to Build Worlds Largest, Most Advanced Automated Pharmacy in Central Indiana
9. Anthem Blue Cross and Blue Shield in Indiana Releases State Health Index
10. Brown Mackie College - Indianapolis Announces New Degree Program in Occupational Therapy
11. HHS Approves Medicaid Waiver to Create New Indiana Health Plan for Uninsured Hoosiers
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:Barr Confirms Patent Challenge of Xyzal(R), 5mg Tablets 2Health News:Barr Confirms Patent Challenge of Xyzal(R), 5mg Tablets 3Health News:Pill Could Boost Sports Performance 2Health News:Get Straight A's in Snacking with Supercharged Superfruits from Fruitaceuticals! 2Health News:'Who's Who' Weight Specialist Martin Schiff, M.D., 86, Devoting Rest of Life to Spreading Truth About Diets, Won't Accept Compensation From Anyone, Sending Complete Guide Free to All 2Health News:Liver damage in hepatitis C patients could be treated with warfarin, says study 2Health News:Liver damage in hepatitis C patients could be treated with warfarin, says study 3Health News: Freescale and Monebo Launch ECG-on-a-Chip Platform Solution to Aid Heart Monitoring : Advanced Hardware and Software Technology Designed to Enable More Efficient and Higher Quality Cardiac Care 2
Breaking Medicine Technology:Chinese-American Women & Korean-American Women at Highest Risk for Developing Diabetes During Pregnancy 2Chinese-American Women & Korean-American Women at Highest Risk for Developing Diabetes During Pregnancy 3Chinese-American Women & Korean-American Women at Highest Risk for Developing Diabetes During Pregnancy 4Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 2Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 3Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 4Genomic Health Announces Publication of Study of Oncotype DX(R) in Node-Positive Breast Cancer That Identifies Patients Who Do Not Appear to Benefit From Chemotherapy 5Onyx Pharmaceuticals to Webcast Analyst Briefing on Development Program 2Autism Support Network Launches Enhanced Features Adds Thousands of New Members Globally 57318 1Autism Support Network Launches Enhanced Features Adds Thousands of New Members Globally 57318 2Video 3A Teen Girls Less Active but Triple Play Program Bucks Trend 57317 1Video 3A Teen Girls Less Active but Triple Play Program Bucks Trend 57317 2Video 3A Teen Girls Less Active but Triple Play Program Bucks Trend 57317 3Video 3A Teen Girls Less Active but Triple Play Program Bucks Trend 57317 4Mylans Matrix Receives Tentative FDA Approval Under PEPFAR for Efavirenz Lamivudine and Tenofovir Disoproxil Fumarate Tablets 57314 1Mylans Matrix Receives Tentative FDA Approval Under PEPFAR for Efavirenz Lamivudine and Tenofovir Disoproxil Fumarate Tablets 57314 2
Other Medicine Technology:Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 2Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 3Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 4Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 5Update From Mipomersen Extended Dosing Study Continues to Show That Mipomersen Is Well Tolerated and Maintains Activity in Patients Treated for Up to 16 Months 6Poniard Pharmaceuticals' Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial 2Poniard Pharmaceuticals' Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial 3Poniard Pharmaceuticals' Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial 4Poniard Pharmaceuticals' Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial 5